Kaken Pharmaceutical , Ltd. EBIT

Kaken Pharmaceutical , Ltd. (KKPCF) currently reports a EBIT of $11B as of June 2026. That compares with $18B in the prior-year period — down 40.0% year over year. That is below the sector sector average of $2.6T. Use the charts on this page to explore Kaken Pharmaceutical , Ltd.'s EBIT history and peer comparisons.

Kaken Pharmaceutical , Ltd.'s EBIT decreased from $18B to $11B — a 40.0% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Kaken Pharmaceutical , Ltd.'s EBIT of $11B is lower than the its sector sector average of $2.6T. That is roughly 99.6% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Kaken Pharmaceutical , Ltd. reported $11B in EBIT as of June 2026. That compares with $18B in the prior-year period — down 40.0% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current EBIT of $11B, then check the historical chart for trend and the peer comparison chart for relative positioning. The sector average is $2.6T. From there, open related valuation or income-statement pages for Kaken Pharmaceutical , Ltd., and consider following KKPCF for alerts when major investors trade the stock.